Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.

source https://finance.yahoo.com/news/bristol-myers-bmy-opdivo-shows-151303957.html?.tsrc=rss